Comment on CMS-2026-1256-0002
GSKOpposeBusiness
Summary: GSK, a global biopharmaceutical company, opposes CMS's proposal to repeal the New Technology Add-on Payment (NTAP) alternative pathway for Qualified Infectious Disease Products (QIDP). The company argues that removing this pathway would stifle antimicrobial innovation, increase the costs associated with antimicrobial resistance (AMR), and delay patient access to critical new treatments.
Please find attached GSK's comment letter on the FY 2027 Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital Prospective Payment System (LTCH PPS) [CMS-1849-P].